key: cord-1004680-a8a5iryz
authors: Miwa, Maki; Nakajima, Mikio; Kaszynski, Richard H.; Hamada, Shoichiro; Ando, Hitoshi; Nakano, Tomotsugu; Shirokawa, Masamitsu; Goto, Hideaki
title: Abnormal pulmonary function and imaging studies in critical COVID-19 survivors at 100 days after the onset of symptoms
date: 2021-06-08
journal: Respir Investig
DOI: 10.1016/j.resinv.2021.05.005
sha: 04322f72c255899cd815199484cba8717ccda4b3
doc_id: 1004680
cord_uid: a8a5iryz

BACKGROUND: The long-term repercussions of critical COVID-19 on pulmonary function and imaging studies remains unexplored. In this study, we investigated the pulmonary function and computed tomography (CT) findings of critical COVID-19 patients approximately 100 days after symptom onset. METHODS: We retrospectively extracted data on critical COVID-19 patients who received invasive mechanical ventilation during hospitalization from April to December 2020 and evaluated their pulmonary function, residual respiratory symptoms, and radiographic abnormalities on CT. RESULTS: We extracted 17 patients whose median age was 63 (interquartile range [IQR], 59–67) years. The median lengths of hospitalization and mechanical ventilation were 23 (IQR, 18–38) and 9 (IQR, 6–13) days, respectively. At 100 days after symptom onset, the following pulmonary function abnormalities were noted in 8 (47%) patients: a diffusion capacity of the lung for carbon monoxide (%DL(CO)) of <80% for 6 patients (35%); a percent vital capacity (%VC) of <80% for 4 patients (24%); and a percent forced expiratory volume (FEV(1)%) of <70%for 1 patient (6%) who also presented with %DL(CO) and %VC abnormalities. Twelve (71%) patients reported residual respiratory symptoms and 16 (94%) showed abnormalities on CT. CONCLUSIONS: Over 90% of the critical COVID-19 patients who underwent invasive mechanical ventilation continued presenting with abnormal imaging studies and 47% of the patients presented with abnormal pulmonary function 100 days after symptom onset. The extent of the residual CT findings might be associated with the degree of abnormal pulmonary function in critical COVID-19 survivors.

As the body of literature concerning the coronavirus disease 2019 (COVID-19) expands, the pathophysiology and clinical manifestations of acute COVID-19 have become relatively common knowledge. Recovery times from COVID-19 drastically differ between patients and are highly dependent on the presence or absence of various risk factors that contribute to disease severity, such as age, body mass index, and underlying comorbidities. (1) (2) (3) Although the clinical hallmarks are well-described, many symptoms are known to carry over into the recovery period, even after the acute phase has subsided. The most common persistent respiratory manifestations documented to date include cough, chest distress, and dyspnea-especially in those with severe/critical disease. (4) An emerging topic of investigation under the current pandemic is the characterization of pulmonary function in COVID-19 survivors. (5-7) A recent report showed impaired diffusion capacity of the lung for carbon monoxide (DL CO ) as the most common pulmonary function-related finding in COVID-19 patients on the day of discharge. (5) Another study examined the issue from a long-term perspective and found that COVID-19 patients requiring high-flow nasal oxygen therapy, non-invasive positive ventilation, or invasive mechanical ventilation had impaired DL CO six months after the onset of symptoms. (7) J o u r n a l P r e -p r o o f Apart from the investigations centered around pulmonary function, some studies have examined post-recovery imaging studies. One report showed lingering radiographic and physiological abnormalities in 71% (39 out of 55 patients) of COVID-19 patients three months after discharge. (8) According to the same study, approximately half the patients presented with abnormalities spanning 1-3 lung segments, as examined via computed tomography (CT).

While informative, most of these studies excluded critical COVID-19 cases.

Long-term sequelae are of particular importance among critical cases presenting with respiratory symptoms extending beyond the recovery period; however, the long-term effects on pulmonary function following a critical COVID-19 remain largely unknown. Thus, the aim of the present study was to examine the pulmonary function and CT findings of patients with critical COVID-19 100 days after the onset of symptoms.

We retrospectively extracted data on patients hospitalized from April 2020 to December 2020 with laboratory confirmed COVID-19. We included critical COVID-19 patients who received J o u r n a l P r e -p r o o f invasive mechanical ventilation during hospitalization and underwent a pulmonary function test and CT scan at approximately 100 days after the onset of symptoms. We excluded patients who i) expired in the hospital, ii) were transferred to other facilities and iii) were lost during the follow-up.

The patient characteristics included age, sex, smoking history, past medical history (i.e., chronic obstructive pulmonary disease, bronchial asthma, interstitial lung disease and diabetes mellitus), length of mechanical ventilation, and length of hospitalization.

The primary outcome was pulmonary function testing approximately 100 days after the onset of symptoms. The pulmonary function tests were performed by qualified technicians in the hospital. The assessments included the following respiratory parameters: vital capacity (VC); functional vital capacity (FVC); forced expiratory volume in one second (FEV 1 ); and the DL CO . The DL CO was measured using the single-breath test. We calculated the %DL CO (DL CO /predicted DL CO ), %VC (VC/predicted VC) and FEV 1 % (FEV 1 /FVC). The abnormal J o u r n a l P r e -p r o o f values were defined as %DL CO <80%, %VC <80% and FEV 1 % <70%.

The secondary outcomes were residual respiratory symptoms and radiographic abnormalities on CT at 100 days after the onset of symptoms. The residual respiratory symptoms were defined as cough, sputum, and dyspnea on effort and/or hoarseness, and the presence or absence of these symptoms was examined at the 100-day follow-up. Dyspnea on effort was defined as a score ≥2 using the modified Medical Research Council dyspnea scale.

(9)(10) The abnormalities on CT were evaluated by a single radiologist and two pulmonologists, both of whom are Board Certified members of the Japanese Respiratory Society. To quantify the extent of the pulmonary abnormalities, CT scores were assigned based on the area involved for each of the five lung lobes as follows: 0, no involvement; 1, <5% involvement; 2, 5-25% involvement; 3, 26-49% involvement; 4, 50-75% involvement; and 5, >75% involvement. The total CT severity score, which ranged from 0 to 25, was calculated by summing the individual lobar scores. (11) In order to identify any potential factors contributing to an impaired %DL CO value, we examined the characteristics and outcomes for patients with and without impaired %DL CO values.

J o u r n a l P r e -p r o o f

This study was approved by the Institutional Review Board of the Tokyo Metropolitan Hiroo Hospital (approval number, J-70). Regardless of the anonymous nature of the data, informed consent was obtained from all the participants.

The continuous variables are reported as the median and interquartile range (IQR), and the categorical variables are reported as the number and percentage. The continuous variables were compared using Wilcoxon rank-sum tests, and the categorical variables were compared using the Fisher's exact test. The threshold for significance was a p-value of 0.05. All the analyses were performed using Stata MP15 (StataCorp, College Station, TX, USA).

After application of the inclusion and exclusion criteria, we extracted 17 patients with critical COVID-19 for a follow-up examination approximately 100 days after onset of the symptoms (Figure 1) . Fourteen (82%) of the patients were men, and the median age of all the patients J o u r n a l P r e -p r o o f was 63 (IQR, 59-67) years. Eleven (65%) patients were current or past smokers. The median length of hospitalization was 23 (IQR, 18-38) days, and the median length of mechanical ventilation was 9 (IQR, 6-13) days ( Table 1 ).

An overview of the pulmonary function tests conducted during this study is provided in Table 2 . At 100 days after the onset of symptoms, 8 (47%) patients showed abnormal pulmonary function. The median %VC, FEV 1 %, and %DL CO values were within the normal limits at 93.9%, 84.5%, and 82.1%, respectively (Figure 2) . However, the following abnormalities were documented: a %DL CO <80% for 6 patients (35%); a %VC <80% for 4 patients (24%); and an FEV 1 % for 1 patient (6%) who also presented with %DL CO and %VC abnormalities ( Table 2 ). The patient who experienced the greatest reduction in the %DL CO underwent a follow-up pulmonary function test 300 days after the onset of symptoms. For this patient, the %VC and %DL CO values improved from 54.6% to 69.1%, and 43.4% to 83.1%, respectively. Another patient was placed on veno-venous extracorporeal membrane oxygenation for 28 days, underwent a tracheostomy on the 25 th hospital day, was liberated from mechanical ventilation on the 55 th hospital day, and had the tracheal cannula removed Table 3 shows the outcomes for each patient at 100 days after the onset of symptoms.

Four patients with %VC values <80% had relatively high CT scores. The characteristics and outcomes for the patients with and without impaired %DL CO values are provided in Table 4 .

Although no significant differences were observed between the patients with and without impaired %DL CO values, the CT scores tended to be higher and the percentage of patients with consolidations tended to be higher percentage for the patients with impaired %DL CO values.

In the present study, we investigated the pulmonary function of critical COVID-19 patients patients who required invasive mechanical ventilation, and long-term outcomes (100 days) were evaluated.

In the present study, 94% of the patients had CT abnormalities at approximately 100 days after symptom onset. This percentage is higher than previous COVID-19 reports because we exclusively examined critical cases. There were several limitations associated with this study. First, the sample size was limited, as only 17 patients were enrolled in the study. Although a larger sample size would have been ideal, the number of surviving critical COVID-19 patients is relatively low, making recruitment for a long-term follow-up study challenging. Second, we could not assess

Over 90% of the critical COVID-19 patients who underwent invasive mechanical ventilation continued to present with abnormal CTs at the 100-day follow-up, and approximately half of these patients showed impairments of long-term pulmonary function.

The extent and area of the residual findings on CT might be associated with the degree of the abnormal pulmonary function observed in critical COVID-19 survivors. 

Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia

Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study

Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)

Clinical characteristics and follow-up analysis of 324 discharged covid-19 patients in shenzhen during the recovery period

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Modified Medical Research Council Dyspnea Scale in GOLD Classification Better Reflects Physical Activities of Daily Living

The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study

Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia

Pulmonary function tests for diagnosing lung disease

Risk of COPD with obstruction in active smokers with normal spirometry and reduced diffusion capacity

One-year outcomes in survivors of the acute respiratory distress syndrome

Follow-up studies in COVID-19 recovered patients -is it mandatory?

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors

Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection

Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up

Pulmonary long-term consequences of COVID-19 infections after hospital discharge

Chest CT in COVID-19 pneumonia: what are the findings in mid-term follow-up?

VC, vital capacity; FVC, forced vital capacity; FEV, forced expiratory volume; DL CO , diffusion capacity of the lung for carbon monoxide

GGO, ground-grass opacity * Including cough, sputum

All authors are required to disclose any COI within 3 calendar years preceding the current year, prior to the submission of any manuscript in the subject matter of which any company, entity, or organization has an interest.